Advances in the discovery and testing of colorectal cancer genes hopefully will make the identification of cohorts of patients at high risk for developing cancer more likely. The development of new screening tests is underway and hopefully this will be fruitful. Non steroidal anti-inflammatory drug use has been shown to reduce risk for colorectal cancer. If agents such as the selective COX-2 inhibitors prove to have fewer adverse effects than nonselective NSAIDs, the risk to benefit ratio might improve. Human clinical trials evaluating the anti-neoplastic effects of selective COX-2 inhibitors are underway to assess the usefulness of these agents for prevention and/or treatment of colorectal cancer.
|Original language||English (US)|
|Number of pages||4|
|State||Published - Dec 1 1999|
- Colorectal cancer
ASJC Scopus subject areas